Nrf2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic parkinson's disease

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Cook, Anthony L ^a,e   Vitale, Alejandra M ^a   Ravishankar, Sugandha ^a   Matigian, Nicholas ^a   Sutherland, Greg T ^a   Shan, Jiangou ^a   Sutharsan, Ratneswary ^a   Perry, Chris ^a,b   Silburn, Peter A ^a,c   Mellick, George D ^a   Whitelaw, Murray L ^d   Wells, Christine A ^a   Mackay Sim, Alan ^a   Wood, Stephen A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR NRF2; 3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; 3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2H-TETRAZOLIUM; SULFORAFAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIOCYANIC ACID DERIVATIVE;

ARTICLE; CELL METABOLISM; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; CASE CONTROL STUDY; CELL LINE; DRUG EFFECT; FEMALE; GENE SILENCING; GENETICS; MALE; METABOLISM; OLFACTORY EPITHELIUM; PATHOLOGY;

CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE SILENCING; GLUTATHIONE; HUMANS; MALE; NF-E2-RELATED FACTOR 2; OLFACTORY MUCOSA; PARKINSON DISEASE; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; THIOCYANATES;

EID: 79959776301     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021907     Document Type: Article

References (76)

1. Dawson TM, Dawson VL, (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822.
2. Terzioglu M, Galter D, (2008) Parkinson's disease: genetic versus toxin-induced rodent models. Febs J 275: 1384-1391.
3. Thomas B, Beal MF, (2007) Parkinson's disease. Hum Mol Genet 16: R183-194.
4. Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, et al. (2009) Prevalence of smell loss in Parkinson's disease--a multicenter study. Parkinsonism Relat Disord 15: 490-494.
5. Feron F, Perry C, McGrath JJ, Mackay-Sim A, (1998) New techniques for biopsy and culture of human olfactory epithelial neurons. Arch Otolaryngol Head Neck Surg 124: 861-866.
6. Leung CT, Coulombe PA, Reed RR, (2007) Contribution of olfactory neural stem cells to tissue maintenance and regeneration. Nat Neurosci 10: 720-726.
7. Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, et al. (2010) Disease-specific, neurosphere-derived cells as models for brain disorders Disease Models and Mechanisms 3: 785-798.
8. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, et al. (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7: 139-148.
9. Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, et al. (2009) Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat Disord 15: 105-109.
10. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, et al. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520.
11. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, et al. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355.
12. Sofic E, Lange KW, Jellinger K, Riederer P, (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-130.
13. Dunigan DD, Waters SB, Owen TC, (1995) Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH- and NADPH-dependent dehydrogenase activity. Biotechniques 19: 640-649.
14. Segu VB, Li G, Metz SA, (1998) Use of a soluble tetrazolium compound to assay metabolic activation of intact beta cells. Metabolism 47: 824-830.
15. Martin HL, Teismann P, (2009) Glutathione--a review on its role and significance in Parkinson's disease. FASEB J 23: 3263-3272.
16. Nguyen T, Nioi P, Pickett CB, (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295.
17. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86.
18. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J, (2009) The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin Ther Targets 13: 319-329.
19. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, et al. (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29: 493-502.
20. Lee JM, Shih AY, Murphy TH, Johnson JA, (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278: 37948-37956.
21. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, et al. (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 27: 13997-14006.
22. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, et al. (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66: 75-85.
23. Katsuoka F, Motohashi H, Engel JD, Yamamoto M, (2005) Nrf2 transcriptionally activates the mafG gene through an antioxidant response element. J Biol Chem 280: 4483-4490.
24. Lee OH, Jain AK, Papusha V, Jaiswal AK, (2007) An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem 282: 36412-36420.
25. Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, et al. (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46: 443-453.
26. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98: 3410-3415.
27. Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, et al. (2005) Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 203: 529-537.
28. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, et al. (2007) Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res 67: 546-554.
29. Loignon M, Miao W, Hu L, Bier A, Bismar TA, et al. (2009) Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther 8: 2432-2440.
30. Leonard MO, Kieran NE, Howell K, Burne MJ, Varadarajan R, et al. (2006) Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 20: 2624-2626.
31. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, et al. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278: 8135-8145.
32. Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, et al. (2006) Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66: 2488-2494.
33. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, et al. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203.
34. He CH, Gong P, Hu B, Stewart D, Choi ME, et al. (2001) Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J Biol Chem 276: 20858-20865.
35. Warabi E, Takabe W, Minami T, Inoue K, Itoh K, et al. (2007) Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species. Free Radic Biol Med 42: 260-269.
36. Knight TR, Choudhuri S, Klaassen CD, (2008) Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. Toxicol Sci 106: 329-338.
37. Venugopal R, Jaiswal AK, (1998) Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17: 3145-3156.
38. Venugopal R, Jaiswal AK, (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 93: 14960-14965.
39. Blank V, (2008) Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? J Mol Biol 376: 913-925.
40. Jancova P, Anzenbacher P, Anzenbacherova E, (2010) Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154: 103-116.
41. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, et al. (2007) Identification of polymorphic antioxidant response elements in the human genome. Hum Mol Genet 16: 1188-1200.
42. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, et al. (2010) Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 11: 36.
43. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG, (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352: 1344-1346.
44. Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, et al. (2007) Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup Environ Med 64: 673-680.
45. Elbaz A, Moisan F, (2008) Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 21: 454-460.
46. Le Couteur DG, Muller M, Yang MC, Mellick GD, McLean AJ, (2002) Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev Environ Health 17: 51-64.
47. Mellick GD, (2006) CYP450, genetics and Parkinson's disease: gene x environment interactions hold the key. J Neural Transm Suppl pp. 159-165.
48. Lewis KN, Mele J, Hayes JD, Buffenstein R, (2010) Nrf2, a Guardian of Healthspan and Gatekeeper of Species Longevity. Integr Comp Biol 50: 829-843.
49. Leiser SF, Miller RA, (2010) Nrf2 signaling, a mechanism for cellular stress resistance in long-lived mice. Mol Cell Biol 30: 871-884.
50. Duan W, Zhang R, Guo Y, Jiang Y, Huang Y, et al. (2009) Nrf2 activity is lost in the spinal cord and its astrocytes of aged mice. In Vitro Cell Dev Biol Anim 45: 388-397.
51. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, et al. (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 101: 3381-3386.
52. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933-2938.
53. Hindle JV, (2010) Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39: 156-161.
54. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D, (2009) Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 24: 979-983.
55. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, et al. (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 20: 1159-1170.
56. Clark J, Simon DK, (2008) Transcribe to Survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal.
57. Berridge MV, Herst PM, Tan AS, (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152.
58. Cory AH, Owen TC, Barltrop JA, Cory JG, (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212.
59. Schapira AH, (2010) Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol 224: 331-335.
60. Parker WD Jr, Boyson SJ, Parks JK, (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723.
61. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y, (1992) Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 4: 27-34.
62. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, et al. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37: 714-722.
63. Esteves AR, Lu J, Rodova M, Onyango I, Lezi E, et al. (2010) Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J Neurochem 113: 674-682.
64. Dhakshinamoorthy S, Jaiswal AK, (2000) Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:Quinone oxidoreductase1 gene. J Biol Chem 275: 40134-40141.
65. Yang H, Ko K, Xia M, Li TW, Oh P, et al. (2010) Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice. Hepatology 51: 1291-1301.
66. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, et al. (2005) Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 25: 8044-8051.
67. Katsuoka F, Motohashi H, Tamagawa Y, Kure S, Igarashi K, et al. (2003) Small Maf compound mutants display central nervous system neuronal degeneration, aberrant transcription, and Bach protein mislocalization coincident with myoclonus and abnormal startle response. Mol Cell Biol 23: 1163-1174.
68. Shavit JA, Motohashi H, Onodera K, Akasaka J, Yamamoto M, et al. (1998) Impaired megakaryopoiesis and behavioral defects in mafG-null mutant mice. Genes Dev 12: 2164-2174.
69. Hwang YP, Jeong HG, (2008) The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett 582: 2655-2662.
70. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, et al. (2003) PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett 546: 181-184.
71. Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y, (2009) Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell 20: 1606-1617.
72. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, et al. (2005) Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A 102: 13670-13675.
73. Aleyasin H, Rousseaux MW, Marcogliese PC, Hewitt SJ, Irrcher I, et al. (2010) DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci U S A 107: 3186-3191.
74. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW, (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506.
75. Chu Y, Kordower JH, (2010) Lewy body pathology in fetal grafts. Ann N Y Acad Sci 1184: 55-67.
76. Cook AL, Chen W, Thurber AE, Smit DJ, Smith AG, et al. (2009) Analysis of cultured human melanocytes based on polymorphisms within the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P loci. J Invest Dermatol 129: 392-405.